BACKGROUND The first CE-approved bioresorbable vascular scaffold (BVS) is effective at treating simple lesions and stable coronary artery disease, but it has yet to be assessed versus the best-in-class drug-eluting stents (DES).
were similar, however, when EES was compared with BES (11, 12) . Furthermore, Natsuaki et al. (13) found BES to be noninferior to EES for in-stent late lumen loss (LLL) at 8 months.
More recently, everolimus-eluting bioresorbable vascular scaffold stents (BVS) have been developed with the aim to further improve late outcomes. The Absorb device (Abbott Vascular, Santa Clara, California) is the first CE-approved BVS. The prospective, open-label, 2-stage ABSORB study of 131 patients was conducted in Europe and New Zealand and led to approval of the Absorb BVS by the European Union in January 2011 to treat coronary artery lesions (14) . The reported LLL was 0.27 mm at 12 months, and the composite endpoint major acute coronary event (MACE) rate was 6.8% at 2-year follow-up (15, 16) .
Due to its resorption kinetics, BVS radial strength is disturbed 6 to 12 months after implantation. This phenomenon could be responsible for the higher restenosis rate compared with metallic platforms at midterm, especially in complex lesions. Its noninferiority to EES is currently under investigation in the multicenter randomized ABSORB II trial, in which 500 patients are anticipated to enroll (17) . Published head-to-head data on BVS compared with EES or BES are lacking. We therefore sought to compare the efficacy, at midterm, of the Absorb BVS, the Promus Element EES (Boston Scientific, Marlborough, Massachusetts), and Biomatrix Flex BES (Biosensors Europe SA, Morges, Switzerland) using LLL as an early marker of restenosis (18, 19) in all-comer patients.
Assuming similar outcomes for the primary endpoint of LLL between BES and EES as suggested by the NEXT (11) , and EVERBIO (Everolimus-Versus Biolimus-Eluting Stents in All-Comers) trial (12) , which demonstrated similar target lesion revascularization (TLR) rates, both DES were unified as 1 comparator.
METHODS
STUDY DESIGN AND PATIENTS. EVERBIO II was a single-center, assessor-blinded, randomized study (20) . Between November 2012 and November 2013, Patient randomization was performed after lesion preparation on the basis of computer-generated random numbers. Allocation was concealed in sealed nontransparent numbered envelopes. Only the outcome assessors and data analysts were blinded to the intervention.
The Absorb BVS (Abbott Vascular) has a poly-DL-lactide coating releasing everolimus. The scaffold body is semi-crystalline poly-L-lactide, which is completely degraded via hydrolysis and bioresorbed within 2 years via the Krebs cycle. The scaffold has 150-mm struts.
The Promus Element stent (Boston Scientific) consists of a platinum chromium alloy with everolimus (100 mg/cm 2 ) applied in a durable, biocompatible acrylic polymer and fluorinated copolymer.
The Biomatrix Flex stent (Biosensors Europe SA) consists of stainless steel (strut thickness of 112 mm) with only abluminal coating with a biodegradable polymer layer (20 mm) that dissolves 6 to 9 months after implantation and from which the lipophilic antiproliferative drug biolimus elutes.
Procedures were performed via the femoral or radial artery with a 5-F to 6-F guiding catheter. The EVERBIO II Trial computation and angiographic measurements. All CEAC members were blinded to stent allocation. STATISTICAL ANALYSES. This trial was powered for superiority of DES over BVS for the primary endpoint of LLL at 9 months. On the basis of published LLL data, we assumed a difference of 0.2 mm in LLL at 9 months (BES/EES 0.3 mm vs. BVS 0.5 mm; SD 0.5 mm). Of note, the assumed LLL of 0.5 mm in the BVS group was based on: 1) the hypothesis that LLL would be maximal at 6 to 12 months (LLL of 0.7 to 0.9 mm, with a peak in pigs at 3 to 6 months) (21); and 2) the hypothesis that LLL would be greater in complex lesions such as in the EVERBIO II trial than that expected in simple lesions such as in the ABSORB B cohort (LLL of 0.2 mm at 6 months) due to a higher rate of scaffold recoil (with or without premature fracture) (22) . On the basis of these criteria, the sample size of 240 patients was considered to achieve a power of 90%. This allowed for a dropout rate of 20%, in which case the study would still yield a power of 83%. Sample size calculations were performed us- were enrolled and randomized to BVS (n ¼ 80), EES (n ¼ 80), or BES (n ¼ 80) implantation. Two patients randomized to BVS were excluded due to important protocol violations (did not receive study stent). The total dropout rate was 9.2%, with 8 (10%) in the EES, 5 (6.3%) in the BES, and 9 (11.5%) in the BVS groups who withdrew consent for followup angiography; 216 patients (90.8%) underwent 9-month follow-up angiography. Baseline clinical characteristics were similar in both groups ( Table 1) .
Mean age of participants was 65 AE 11 years, a majority of whom were men (79%); 23% had diabetes, 17% a prior history of MI, and 31% had already undergone PCI. The clinical presentation was ACS in 39% of cases.
The baseline angiographic and procedural characteristics were generally well balanced ( Table 3 . Due to the longer scaffold with greater diameter, in-segment dimensions tended to be greater after BVS implantation than after EES/BES implantation. On the other hand, due to greater acute recoil in BVS (9.5 AE 6.5% vs. 6.6 AE 4.7%; p < 0.01), post-procedural in-stent dimensions tended to be lower with BVS compared with EES/BES. The EVERBIO II Trial Puricel et al. In-stent LLL is considered a particularly robust endpoint for discrimination of new coronary stents for which binary rates are anticipated to be low. It is highly predictive of clinical revascularization rates, correlating with binary restenosis and TLR, and especially useful for "early" trials, such as ours, with limited sample size (19, 25) .
To better analyze BVS effectiveness in complex patients, we deliberately chose to compare it with the best competitors and at its weakest time point. On the basis of animal evidence, we speculated that BVS failure would be 6 to 12 months post-implantation. As Our reassuring findings revealed excellent in-stent LLL for both groups in a patient population with a MLD ¼ minimal lumen diameter; RVD ¼ reference vessel diameter; other abbreviations as in Table 1 . At 9 months, metallic stents were not superior to BVS for in-stent late lumen loss (LLL); in-segment LLL was higher with BVS, significantly so versus BES (p ¼ 0.03). Abbreviations as in Figure 1 . Values are n (%).
TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization; other abbreviations as in Table 1 . The EVERBIO II Trial
